Therapeutic Lifestyle Changes Improve HDL Function by Inhibiting Myeloperoxidase-Mediated Oxidation in Patients With Metabolic Syndrome

Diabetes Care. 2018 Nov;41(11):2431-2437. doi: 10.2337/dc18-0049. Epub 2018 Sep 10.

Abstract

Objective: Phagocyte-derived myeloperoxidase (MPO) and proinflammatory HDL are associated with metabolic syndrome (MetS) and increased cardiovascular disease risk. Therapeutic lifestyle changes (TLCs), such as a Mediterranean diet and exercise, decrease this risk. However, the link among TLCs, HDL, and MPO-mediated oxidative stress remains unclear.

Research design and methods: In this study, we characterized changes in cholesterol efflux capacity (CEC), a metric of HDL function; MPO-mediated oxidation; and the HDL proteomic profile in 25 patients with MetS who underwent 12 weeks of TLCs.

Results: After 12 weeks, before significant changes to HDL levels, most MetS components improved as a result of the TLCs. CEC was significantly increased, and HDL MPO oxidation products, 3-chlorotyrosine and 3-nitrotyrosine, were decreased with TLCs. The changes in CEC were inversely related to the unit changes in 3-chlorotyrosine after we controlled for changes in the other MetS components. TLCs did not remodel the HDL proteome.

Conclusions: In summary, TLCs improved HDL function by inhibiting MPO-mediated oxidative stress even before appreciable changes in HDL levels.

Trial registration: ClinicalTrials.gov NCT00907127.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Animals
  • Biological Transport
  • Caloric Restriction
  • Cells, Cultured
  • Cholesterol, HDL / metabolism*
  • Diet Therapy
  • Diet, Mediterranean
  • Exercise Therapy
  • Female
  • Humans
  • Life Style*
  • Lipoproteins, HDL / metabolism*
  • Male
  • Metabolic Syndrome / metabolism
  • Metabolic Syndrome / therapy*
  • Mice
  • Middle Aged
  • Oxidation-Reduction
  • Oxidative Stress / physiology
  • Patient Education as Topic
  • Peroxidase / antagonists & inhibitors
  • Peroxidase / metabolism
  • Pilot Projects
  • Proteomics
  • Risk Reduction Behavior
  • Young Adult

Substances

  • Cholesterol, HDL
  • Lipoproteins, HDL
  • MPO protein, human
  • Peroxidase

Associated data

  • ClinicalTrials.gov/NCT00907127